Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06589986 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study of Moderately to Severely Active Ulcerative Colitis, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06589986 is a Phase 3 study of Moderately to Severely Active Ulcerative Colitis that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 400 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06589986, a Phase 3 study of Moderately to Severely Active Ulcerative Colitis, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Afimkibart
Study Locations (20)
Florida
- Access Research Institute - Brooksville
- Gastro Florida - Clearwater
- HealthMed Clinical Center Inc. - Coral Gables
- J&A Clinical Research - Doral
- Clinical Research of Osceola, LLC - Kissimmee
- Auzmer Research - Lakeland
- Florida Research Institute - Lakewood - Lakewood Rch
- Homestead Associates in Research, Inc. - Miami
- Allied Biomedical Research Institute, Inc - Miami
California
- Om Research LLC - Lancaster
- UCLA - Los Angeles
- University of California Irvine - Orange
- Stanford Medicine Outpatient Center - Redwood City
- Acclaim Clinical Research, Inc. - San Diego
- UCSF/Medical Center at Mount Zion - San Francisco
- Amicis Research Center - Santa Clarita
Colorado
- Peak Gastroenterology Associates - Colorado Springs
- Peak Gastroenterology Surgery Center - Lone Tree
Alabama
- Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan - Dothan
Arizona
- Arizona Digestive Health, P.C (ADH) - Sun City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2031-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06589986
The ClinicalTrials.gov registry entry for NCT06589986 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderately to Severely Active Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06589986 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06589986 about?
NCT06589986 is a clinical study titled "A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis". This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT06589986?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-09-17. Estimated completion is 2031-01-30.
What conditions does trial NCT06589986 study?
This clinical trial studies the following conditions: Moderately to Severely Active Ulcerative Colitis.
What interventions are being tested in trial NCT06589986?
The interventions under investigation include: Placebo (DRUG), Afimkibart (DRUG).
Who is sponsoring clinical trial NCT06589986?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06589986 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderately to Severely Active Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.